Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Market Cap	234.42B
Revenue (ttm)	12.53B
Net Income (ttm)	-27.47B
Shares Out	77.75M
EPS (ttm)	-372.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,823
Average Volume	177,044
Open	3,000.00
Previous Close	3,000.00
Day's Range	2,930.00 - 3,030.00
52-Week Range	2,900.00 - 7,250.00
Beta	0.91
RSI	33.03
Earnings Date	n/a

About Prestige Biologics

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd. was formerly known...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 334970

Financial Performance

In 2025, Prestige Biologics's revenue was 12.53 billion, an increase of 477.83% compared to the previous year's 2.17 billion. Losses were -27.47 billion, -6.48% less than in 2024.